全文获取类型
收费全文 | 26535篇 |
免费 | 3023篇 |
国内免费 | 1337篇 |
专业分类
耳鼻咽喉 | 131篇 |
儿科学 | 460篇 |
妇产科学 | 480篇 |
基础医学 | 4811篇 |
口腔科学 | 356篇 |
临床医学 | 2151篇 |
内科学 | 4620篇 |
皮肤病学 | 442篇 |
神经病学 | 1432篇 |
特种医学 | 643篇 |
外国民族医学 | 20篇 |
外科学 | 2261篇 |
综合类 | 4120篇 |
现状与发展 | 7篇 |
预防医学 | 1072篇 |
眼科学 | 802篇 |
药学 | 2287篇 |
16篇 | |
中国医学 | 505篇 |
肿瘤学 | 4279篇 |
出版年
2024年 | 30篇 |
2023年 | 604篇 |
2022年 | 720篇 |
2021年 | 1486篇 |
2020年 | 1213篇 |
2019年 | 1150篇 |
2018年 | 1014篇 |
2017年 | 985篇 |
2016年 | 1135篇 |
2015年 | 1257篇 |
2014年 | 1688篇 |
2013年 | 1886篇 |
2012年 | 1657篇 |
2011年 | 1767篇 |
2010年 | 1571篇 |
2009年 | 1516篇 |
2008年 | 1453篇 |
2007年 | 1406篇 |
2006年 | 1221篇 |
2005年 | 977篇 |
2004年 | 785篇 |
2003年 | 690篇 |
2002年 | 529篇 |
2001年 | 539篇 |
2000年 | 437篇 |
1999年 | 345篇 |
1998年 | 289篇 |
1997年 | 285篇 |
1996年 | 208篇 |
1995年 | 217篇 |
1994年 | 225篇 |
1993年 | 183篇 |
1992年 | 159篇 |
1991年 | 118篇 |
1990年 | 107篇 |
1989年 | 120篇 |
1988年 | 102篇 |
1987年 | 76篇 |
1986年 | 69篇 |
1985年 | 105篇 |
1984年 | 69篇 |
1983年 | 51篇 |
1982年 | 53篇 |
1981年 | 70篇 |
1980年 | 73篇 |
1979年 | 42篇 |
1978年 | 47篇 |
1977年 | 32篇 |
1976年 | 44篇 |
1975年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
利用生物信息学技术初步探索芫根调控肠道免疫功能的分子生物学机制。方法 选择雄性SPF级BALB/c小鼠18只,随机分为3组,每组6只。SC1组小鼠每只每次灌胃芫根提取液150 μL,SC2组小鼠每只每次灌胃绞碎芫根原浆悬液150 μL,NC组小鼠每只每次灌胃生理盐水150 μL,连续7 d每日灌胃一次。分别取每组小鼠小肠组织样品提取RNA,总RNA的质检合格后,进行转录组测序。按GO功能和KEGG信号通路对差异表达基因聚类分析揭示差异表达高度富集的免疫相关通路。从免疫角度分析芫根灌胃小鼠小肠组织的基因表达变化情况。结果 转录组测序共检测到27733条 mRNA的表达,SC1组与NC组比较,显著差异表达基因1635个,其中上调差异表达基因1236个,下调差异表达基因399个;SC2组与NC组比较,显著差异表达基因2872个,其中上调差异表达基因2233个,下调差异表达基因639个(P<0.05)。按GO功能和KEGG信号通路聚类分析显示差异表达基因在白介素分泌、干扰素反应、T细胞受体信号通路及维生素和脂肪消化吸收等途径的富集度在两个芫根组中均居于前20位(P<0.01),肠黏膜趋化因子CCL20和巨噬细胞极化标志物CD274等免疫蛋白编码基因差异表达显著且同属于上述多个免疫通路。结论 芫根灌胃小鼠小肠的差异表达基因在白介素分泌、干扰素反应、T细胞受体信号通路、营养物质消化吸收等途径高度富集,提示芫根对肠道免疫系统及肠黏膜功能的调节,其中CD274的表达上调和CCL20的表达下调提示诱导M1型巨噬细胞极化和T细胞活化可能是芫根调控免疫和维护肠道正常结构功能的重要途径。 相似文献
2.
Mixed lineage leukemia 1(MLL1)是组蛋白甲基转移酶SET家族的成员之一。MLL1与WDR5、RbBP5、Ash2L和DPY-30组成MLL1甲基转移酶复合物调控组蛋白H3的第4位赖氨酸的甲基化水平,对造血系统的发育和血细胞的更新至关重要。部分白血病患者体内存在因MLL1基因易位而产生的致癌蛋白——MLL1融合蛋白,MLL1融合蛋白在发挥其致癌作用时需要功能完整的MLL1酶复合物,故靶向MLL1-WDR5的蛋白-蛋白相互作用成为治疗MLL1融合型白血病的潜在策略。本文对MLL1-WDR5蛋白-蛋白相互作用的生物学机制、结构信息以及抑制剂进行了系统的总结,并结合已报道数据对该领域进行了展望,以期为后续研究提供参考。 相似文献
3.
《The Journal of thoracic and cardiovascular surgery》2023,165(1):327-334.e2
ObjectiveSeveral trials have recently reported the safety of pulmonary resection after neoadjuvant immunotherapy with encouraging major pathological response rates. We report the detailed adverse events profile from a recently conducted randomized phase II trial in patients with resectable non–small cell lung cancer treated with neoadjuvant durvalumab alone or with sub-ablative radiation.MethodsWe conducted a randomized phase II trial in patients with non–small cell lung cancer clinical stages I to IIIA who were randomly assigned to receive neoadjuvant durvalumab alone or with sub-ablative radiation (8Gyx3). Secondary end points included the safety of 2 cycles of preoperative durvalumab with and without radiation followed by pulmonary resection. Postoperative adverse events within 30 days were recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).ResultsSixty patients were enrolled and randomly assigned, with planned resection performed in 26 patients in each arm. Baseline demographics and clinical variables were balanced between groups. The median operative time was similar between arms: 128 minutes (97-201) versus 146 minutes (109-214) (P = .314). There was no 30- or 90-day mortality. Grade 3/4 adverse events occurred in 10 of 26 patients (38%) after monotherapy and in 10 of 26 patients (38%) after dual therapy. Anemia requiring transfusion and hypotension were the 2 most common adverse events. The median length of stay was similar between arms (5 days vs 4 days, P = .172).ConclusionsIn this randomized trial, the addition of sub-ablative focal radiation to durvalumab in the neoadjuvant setting was not associated with increased mortality or morbidity compared with neoadjuvant durvalumab alone. 相似文献
4.
5.
6.
- DNA is the sequence that codes for proteins.
- Messenger RNA is transcribed from the DNA sequence of genes and translated into protein.
- It can be difficult to predict how a change in the DNA sequence will affect messenger RNA and protein quantity and quality.
- DNA translocation changes can cause the joining of sequences from two different genes or different parts of the same gene.
- DNA sequencing is often used clinically to predict how DNA changes might affect proteins.
- Alternatively, RNA sequencing can be used as a more direct measure of the effect of DNA changes on the protein products.
- This sequencing is important for identifying changes in cancer that may indicate response to targeted therapy, prognosis, or diagnosis.
7.
8.
《Journal of vascular and interventional radiology : JVIR》2022,33(8):964-971.e2
PurposeTo assess the cost effectiveness of microwave ablation (MWA) and stereotactic body radiotherapy (SBRT) for patients with inoperable stage I non–small cell lung cancer (NSCLC).Materials and MethodsA literature search was performed in MEDLINE with broad search clusters. A decision-analytic model was constructed over a 5-year period. The model incorporated treatment-related complications and long-term recurrence. All clinical parameters were derived from the literature with preference to long-term prospective trials. A healthcare payers’ perspective was adopted. Outcomes were measured in quality-adjusted life years (QALYs) extracted from prior studies and U.S. dollars from Medicare reimbursements and prior studies. Base case calculations, probabilistic sensitivity analysis with 10,000 Monte Carlo simulations, and multiple 1- and 2-way sensitivity analyses were performed.ResultsMWA yielded a health benefit of 2.31 QALYs at a cost of $195,331, whereas SBRT yielded a health benefit of 2.33 QALYs at a cost of $225,271. The incremental cost-effectiveness ratio was $1,480,597/QALY, indicating that MWA is the more cost-effective strategy. The conclusion remains unchanged in probabilistic sensitivity analysis with MWA being the optimal cost strategy in 99.84% simulations. One-way sensitivity analyses revealed that MWA remains cost effective when its annual recurrence risk is <18.4% averaged over 5 years, when the SBRT annual recurrence risk is >1.44% averaged over 5 years, or when MWA is at least $7,500 cheaper than SBRT.ConclusionsMWA appears to be more cost effective than SBRT for patients with inoperable stage I NSCLC. 相似文献
9.
10.
Dan-Dan Shan Qiu-Xian Zheng Jing Wang Zhi Chen 《World journal of gastroenterology : WJG》2022,28(16):1641-1655
Cancer has become the most life-threatening disease in the world. Mutations in and aberrant expression of genes encoding proteins and mutations in noncoding RNAs, especially long noncoding RNAs (lncRNAs), have significant effects in human cancers. LncRNAs have no protein-coding ability but function extensively in numerous physiological and pathological processes. Small nucleolar RNA host gene 3 (SNHG3) is a novel lncRNA and has been reported to be differentially expressed in various tumors, such as liver cancer, gastric cancer, and glioma. However, the interaction mechanisms for the regulation between SNHG3 and tumor progression are poorly understood. In this review, we summarize the results of SNHG3 studies in humans, animal models, and cells to underline the expression and role of SNHG3 in cancer. SNHG3 expression is upregulated in most tumors and is detrimental to patient prognosis. SNHG3 expression in lung adenocarcinoma remains controversial. Concurrently, SNHG3 affects oncogenes and tumor suppressor genes through various mechanisms, including competing endogenous RNA effects. A deeper understanding of the contribution of SNHG3 in clinical applications and tumor development may provide a new target for cancer diagnosis and treatment. 相似文献